Examination of nighttime sleep-related problems during double-blind, placebo-controlled trials of galantamine in patients with Alzheimer's disease

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Current Medical Research and Opinion

• Publication date

  2004-02-18

• Fields of study

  Medicine

• Identifiers
  DOI 10.1185/030079904125003214PMID 15119989
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The Magnitude of Dementia Occurrence in the World

  2003cited by this paper
• Sleep-related outcomes in persons with mild to moderate Alzheimer disease in a placebo-controlled trial of galantamine.

  2003cited by this paper
• Alzheimer disease in the US population: prevalence estimates using the 2000 census.

  2003cited by this paper
• Co-use of donepezil and hypnotics among Alzheimer's disease patients living in the community.

  2003cited by this paper
• The tolerability and safety of cholinesterase inhibitors in the treatment of dementia.

  2002cited by this paper
• Sleep Disturbances in Patients with Alzheimer’s Disease

  2001cited by this paper
• Donepezil compared to rivastigmine in Alzheimer's disease: Similar efficacy but better tolerability and physician and caregiver satisfaction in a multinational randomized trial

  2001cited by this paper
• Effects of a flexible galantamine dose in Alzheimer's disease: a randomised, controlled trial

  2001cited by this paper
• A 5-month, randomized, placebo-controlled trial of galantamine in AD

  2000cited by this paper
• The new cholinesterase inhibitors for Alzheimer's disease, Part 1: their similarities are different.

  2000cited by this paper
• Galantamine in AD

  2000cited by this paper
• The new cholinesterase inhibitors for Alzheimer's disease, Part 2: illustrating their mechanisms of action.

  2000cited by this paper
• Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trial

  2000cited by this paper
• Cholinesterase inhibitors: A new class of psychotropic compounds.

  2000cited by this paper
• Predictors of institutionalization of cognitively impaired elders: family help and the timing of placement.

  2000cited by this paper
• Galantamine is an allosterically potentiating ligand of the human α4/β2 nAChR

  2000cited by this paper
• Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension

  2000cited by this paper
• Sleep Disorders Medicine. Basic Science, Technical Considerations and Clinical Aspects.

  1999cited by this paper
• The Effects of Donepezil in Alzheimer’s Disease – Results from a Multinational Trial1

  1999cited by this paper
• Characteristics of Sleep Disturbance in Community-Dwelling Alzheimer's Disease Patients

  1999cited by this paper
• Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial.

  1999cited by this paper
• Donepezil Improves Cognition and Global Function in Alzheimer Disease A 15-Week, Double-blind, Placebo-Controlled Study

  1998cited by this paper
• Predictors of institutionalization for people with dementia living at home with a carer

  1998cited by this paper
• Sleep electroencephalographic response to muscarinic and serotonin1A receptor probes in patients with major depression and in normal controls.

  1998cited by this paper
• DONEPEZIL STUDY GROUP. A 24-WEEK, DOUBLE BLIND, PLACEBO-CONTROLLED TRIAL OF DONEPEZIL IN PATIENTS WITH ALZHEIMER'S DIS-EASE

  1998cited by this paper
• Determinants of carer stress in Alzheimer's disease

  1998cited by this paper
• A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease

  1998cited by this paper
• ARICEPT‐INDUCED NIGHTMARES IN ALZHEIMER'S DISEASE: 2 CASE REPORTS

  1998cited by this paper
• Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Donepezil Study Group.

  1998cited by this paper
• Sleep/wake patterns In Alzheimer's disease: relationships with cognition and function

  1995influential reference
• Sleep Disorders in Elderly Persons

  1994cited by this paper
• The Neuropsychiatric Inventory

  1994cited by this paper
• Biochemical Pharmacology of Sleep

  1994cited by this paper
• Timing of sleep and wakefulness in Alzheimer's disease patients residing at home.

  1992cited by this paper
• Sleep Problems and Institutionalization of the Elderly

  1991cited by this paper
• The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research.

  1989cited by this paper
• Fundamentals of Clinical Trials. (2nd ed.).

  1987cited by this paper
• EEG sleep in elderly depressed, demented, and healthy subjects.

  1985cited by this paper
• The organization and regulation of sleep

  1984cited by this paper
• Fundamentals of Clinical Trials

  1982cited by this paper
• Development and use of pharmacological probes of the CNS in man: evidence of cholinergic abnormality in primary affective illness.

  1980cited by this paper
• “Mini-mental state”: A practical method for grading the cognitive state of patients for the clinician

  1975cited by this paper

• Pharmacological and non-pharmacological treatment options for sleep disturbances in Alzheimer’s disease

  2023cites this paper
• Research Progress of Preoperative Sleep Disorder and Postoperative Delirium

  2023cites this paper
• Burden of Insomnia and Sleep Disturbances and the Impact of Sleep Treatments in Patients with Probable or Possible Alzheimer’s Disease: A Structured Literature Review

  2022influential citation
• Impact of Pharmacotherapy on Insomnia in Patients with Alzheimer’s Disease

  2021cites this paper
• Medications that disrupt sleep

  2021cites this paper
• Pharmacotherapies for sleep disturbances in dementia.

  2020cites this paper
• The effect of cholinesterase inhibitors on sleep in the patients with Alzheimer’s disease: an observational prospective study

  2018cites this paper
• Drugs That Disturb Sleep and Wakefulness

  2017cites this paper
• Galantamine for Alzheimer’s Disease and Alzheimer’s Disease with Cerebrovascular Disease

  2016cites this paper
• Pharmacotherapies for sleep disturbances in dementia.

  2016cites this paper
• Sleep disturbances and dementia

  2015cites this paper
• Effects of pharmacological manipulation of the serotonergic/cholinergic systems on sleep structure in two 5-HT1A genotypes: Implications for a model of depression

  2015cites this paper
• Pharmacotherapies for sleep disturbances in Alzheimer's disease

  2015cites this paper
• Galantamine improves sleep quality in patients with dementia

  2015cites this paper
• The effects of galantamine and buspirone on sleep structure: Implications for understanding sleep abnormalities in major depression

  2015cites this paper
• Galantamine-associated nightmares and anxiety.

  2013cites this paper
• Effects of Single Treatment of Anti-Dementia Drugs on Sleep-Wake Patterns in Rats

  2012cites this paper
• Dreaming and hallucinations - continuity or discontinuity? Perspectives from dementia with Lewy bodies.

  2011cites this paper
• Sundown Syndrome in Persons with Dementia: An Update

  2011cites this paper
• [Acetylcholinesterase inhibitors in Alzheimer's disease: further comments on their mechanisms of action and therapeutic consequences].

  2010cites this paper
• Non-pharmacologic management of sleep disturbance in Alzheimer's disease

  2010cites this paper
• [Dreams in normal and pathological aging].

  2010cites this paper
• [Efficacy and safety of rivastigmine (exelon) in the confusion syndrome in the acute phase of ischemic stroke].

  2010cites this paper
• Bibliographie

  2009cites this paper
• Galantamine for the Treatment of BPSD in Thai Patients With Possible Alzheimer's Disease With or Without Cerebrovascular Disease

  2009cites this paper
• Chapitre 15.Sommeil et démences

  2009cites this paper
• The effect of Galantamine on sleep quality in Thai Alzheimer's disease patients.

  2008influential citation
• Importance of circadian rhythmicity in the cholinergic treatment of Alzheimer's disease: focus on galantamine*

  2008cites this paper
• Drug Class Review Newer Drugs for Insomnia

  2008cites this paper
• Importance of circadian rhythmicity in the cholinergic treatment of Alzheimer's disease: focus on galantamine*.

  2008cites this paper
• Drug Class Review on Newer Drugs for Insomnia: Final Report

  2006cites this paper
• Acetylcholinesterase Inhibitors and Sleep Architecture in Patients with Alzheimer’s Disease

  2006cites this paper
• Drug Class Review on Alzheimer's Drugs

  2006cites this paper
• "Sundowning" and other temporally associated agitation states in dementia patients.

  2006cites this paper
• Genetically increased risk of sleep disruption in Alzheimer's disease.

  2006cites this paper
• The Effect of Sleep-Disordered Breathing on Stages of Sleep in Patients With Alzheimer's Disease

  2006cites this paper
• Galantamine for Alzheimer's disease and mild cognitive impairment.

  2006cites this paper
• Circadian Cholinergic Rhythms: Implications for Cholinesterase Inhibitor Therapy

  2006cites this paper
• Original Contribution EFFECT OF GALANTAMINE ON THE SHORT MEMORY OF SPONTANEOUSLY HYPERTENSIVE RATS (SHR) EXPOSED TO INSOMNIA

  2005cites this paper
• Emerging treatment strategies for alzheimer’s disease

  2005cites this paper
• Effects of Galantamine Versus Donepezil on Sleep in Patients With Mild to Moderate Alzheimer Disease and Their Caregivers: A Double-Blind, Head-to-Head, Randomized Pilot Study

  2005cites this paper
• Verwendung von D4 und 5-HT2A Antagonisten, inverse Agonisten oder partielle Agonisten

  2004cites this paper
• Utilisation d'antagonistes, d'agonistes inverses ou d'agonistes partiels d4 et 5ht2a,

  2004cites this paper
• The benefits and risks associated with cholinesterase inhibitor therapy in Alzheimer’s disease

  2004cites this paper